

# Wouter H Van Geffen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5255961/publications.pdf>

Version: 2024-02-01

34  
papers

541  
citations

840776

11  
h-index

713466

21  
g-index

35  
all docs

35  
docs citations

35  
times ranked

841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung volume reduction for emphysema. <i>Lancet Respiratory Medicine</i> , 2017, 5, 147-156.	10.7	104
2	Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 313-324.	10.7	78
3	Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study. <i>Journal of Breath Research</i> , 2016, 10, 036001.	3.0	57
4	Increased levels of (class switched) memory B cells in peripheral blood of current smokers. <i>Respiratory Research</i> , 2009, 10, 108.	3.6	52
5	Differential switching to IgG and IgA in active smoking COPD patients and healthy controls. <i>European Respiratory Journal</i> , 2012, 40, 313-321.	6.7	38
6	Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. <i>The Cochrane Library</i> , 2016, 2016, CD011826.	2.8	30
7	Pleural Adhesion Assessment as a Predictor for Pneumothorax after Endobronchial Valve Treatment. <i>Respiration</i> , 2017, 94, 224-231.	2.6	25
8	Increased neutrophil expression of pattern recognition receptors during <sc>COPD</sc> exacerbations. <i>Respirology</i> , 2017, 22, 401-404.	2.3	24
9	Emerging bronchoscopic treatments for chronic obstructive pulmonary disease. , 2017, 179, 96-101.		23
10	Hyperinflation in COPD exacerbations. <i>Lancet Respiratory Medicine</i> , 2015, 3, e43-e44.	10.7	16
11	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019, 15, e135-e141.	1.3	15
12	Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e647-e653.	2.6	12
13	Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 1269-1277.	2.3	10
14	Quantitative Evaluation of Lobar Pulmonary Function of Emphysema Patients with Endobronchial Coils. <i>Respiration</i> , 2019, 98, 70-81.	2.6	9
15	Changes in ventilation&ndash;perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling. <i>International Journal of COPD</i> , 2018, Volume 13, 833-842.	2.3	8
16	Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1783-1792.	2.3	8
17	Surviving Respiratory Insufficiency with Intensive Care Support in a Pretreated, Extensively Metastasized Patient with an EML4-ALK Translocation. <i>Journal of Thoracic Oncology</i> , 2013, 8, e1-e2.	1.1	7
18	A malignant retroperitoneal mass - A rare presentation of recurrent thymoma. <i>BMJ Case Reports</i> , 2011, 2011, bcr0920114737-bcr0920114737.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Lung volume reduction for emphysema – Authors' reply. Lancet Respiratory Medicine, the, 2017, 5, e24.	10.7	5
20	Identifying Responders and Exploring Mechanisms of Action of the Endobronchial Coil Treatment for Emphysema. Respiration, 2021, 100, 443-451.	2.6	5
21	Autobullectomy in Patients with COPD. Respiration, 2015, 89, 88-88.	2.6	4
22	Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respiratory Medicine, 2020, 171, 106064.	2.9	3
23	Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. The Cochrane Library, 0, , .	2.8	1
24	Changes in FEV1 after recovery from COPD exacerbation are driven by heterogeneous regional changes in airway caliber and hyperinflation. , 2015, , .		1
25	The Smoke-induced Specific Immune Response Differs Between COPD Patients And Healthy Controls. , 2010, , .		0
26	Continuous professional development: elevating thoracic oncology education in Europe. Breathe, 2019, 15, 279-285.	1.3	0
27	Changes in functional respiratory imaging (FRI) endpoints correlate with changes in patient reported outcomes (PRO) after recovering from acute COPD exacerbation. , 2015, , .		0
28	Improvement in FEV1 after acute COPD exacerbations are driven more by changes in hyperinflation than changes in proximal airway volume. , 2015, , .		0
29	The efficacy and safety of CT-guided percutaneous hookwire localization in VATS for pulmonary nodules. , 2016, , .		0
30	Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by electronic nose. , 2016, , .		0
31	Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review. , 2016, , .		0
32	Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. , 2017, , .		0
33	Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC). , 2019, , .		0
34	Mechanisms of action of endobronchial coil treatment. , 2019, , .		0